RU2747877C2 - Аналоги эфр(а) с заместителями - жирными кислотами - Google Patents

Аналоги эфр(а) с заместителями - жирными кислотами Download PDF

Info

Publication number
RU2747877C2
RU2747877C2 RU2018127882A RU2018127882A RU2747877C2 RU 2747877 C2 RU2747877 C2 RU 2747877C2 RU 2018127882 A RU2018127882 A RU 2018127882A RU 2018127882 A RU2018127882 A RU 2018127882A RU 2747877 C2 RU2747877 C2 RU 2747877C2
Authority
RU
Russia
Prior art keywords
egf
ethoxy
peptide
amino
amino acid
Prior art date
Application number
RU2018127882A
Other languages
English (en)
Russian (ru)
Other versions
RU2018127882A3 (enExample
RU2018127882A (ru
Inventor
Дзяньхэ ЧЕН
Йеспер Ф. ЛАУ
Янош Тибор КОДРА
Биргит ВЕЧОРЕК
Ларс ЛИНДЕРОТ
Хеннинг ТЁГЕРСЕН
Салька Эльбёль РАСМУССЕН
Патрик Уилльям ГЭРИБЭЙ
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU2018127882A publication Critical patent/RU2018127882A/ru
Publication of RU2018127882A3 publication Critical patent/RU2018127882A3/ru
Application granted granted Critical
Publication of RU2747877C2 publication Critical patent/RU2747877C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2018127882A 2016-01-13 2017-01-13 Аналоги эфр(а) с заместителями - жирными кислотами RU2747877C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/070791 2016-01-13
CN2016070791 2016-01-13
CNPCT/CN2016/076580 2016-03-17
CN2016076580 2016-03-17
EP16195965 2016-10-27
EP16195965.5 2016-10-27
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Publications (3)

Publication Number Publication Date
RU2018127882A RU2018127882A (ru) 2020-02-13
RU2018127882A3 RU2018127882A3 (enExample) 2020-06-19
RU2747877C2 true RU2747877C2 (ru) 2021-05-17

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018127882A RU2747877C2 (ru) 2016-01-13 2017-01-13 Аналоги эфр(а) с заместителями - жирными кислотами

Country Status (26)

Country Link
US (2) US10822385B2 (enExample)
EP (1) EP3402811B1 (enExample)
JP (2) JP6797926B2 (enExample)
KR (1) KR102417487B1 (enExample)
CN (1) CN108473550B (enExample)
AU (1) AU2017207862B2 (enExample)
BR (1) BR112018013820A2 (enExample)
CA (1) CA3010756A1 (enExample)
CL (1) CL2018001868A1 (enExample)
CO (1) CO2018007440A2 (enExample)
DK (1) DK3402811T3 (enExample)
ES (1) ES2916998T3 (enExample)
HR (1) HRP20220720T1 (enExample)
HU (1) HUE058647T2 (enExample)
IL (1) IL260043A (enExample)
LT (1) LT3402811T (enExample)
MX (1) MX2018008681A (enExample)
MY (1) MY195199A (enExample)
PE (1) PE20181376A1 (enExample)
PH (1) PH12018501502A1 (enExample)
PL (1) PL3402811T3 (enExample)
RS (1) RS63298B1 (enExample)
RU (1) RU2747877C2 (enExample)
SA (1) SA518391996B1 (enExample)
SI (1) SI3402811T1 (enExample)
WO (1) WO2017121850A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60224B1 (sr) 2016-01-13 2020-06-30 Gruenenthal Gmbh Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
HRP20250176T1 (hr) 2016-01-13 2025-04-11 Grünenthal GmbH Derivati 3-((hetero-)aril)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
AU2017207862B2 (en) 2016-01-13 2020-12-17 Novo Nordisk A/S EGF(A) analogues with fatty acid substituents
JP6917379B2 (ja) 2016-01-13 2021-08-11 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
AR107360A1 (es) 2016-01-13 2018-04-25 Gruenenthal Gmbh Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
WO2019016306A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S BIFUNCTIONAL COMPOUNDS
CN111164098A (zh) * 2017-07-19 2020-05-15 诺沃挪第克公司 Egf(a)类似物、其制品、制剂和用途
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University Fatty acid modified human epidermal growth factor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
MA53809A (fr) * 2018-10-05 2022-01-12 Novo Nordisk As Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)
US11633632B2 (en) 2019-03-22 2023-04-25 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
CN114222581A (zh) 2019-08-07 2022-03-22 诺和诺德股份有限公司 包含egf(a)衍生物和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
AU2020378624A1 (en) 2019-11-07 2022-04-21 Novo Nordisk A/S Solid compositions comprising a PCSK9 inhibitor and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP2024527488A (ja) 2021-07-02 2024-07-25 スリーエム イノベイティブ プロパティズ カンパニー 落下防止安全装置と連動される空中リフト
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296694A2 (en) * 2008-04-23 2011-03-23 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
WO2012177741A1 (en) * 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use
RU2528735C2 (ru) * 2008-09-12 2014-09-20 Ринат Ньюросайенс Корпорейшн Антагонисты pcsk9

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909823A2 (en) 2005-07-29 2008-04-16 Amprotein Corporation Chimeric therapeutic agents
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN103052900A (zh) * 2010-08-02 2013-04-17 日本电气株式会社 偏振器和发光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
EP2675470A1 (en) 2011-02-15 2013-12-25 Novo Nordisk A/S Long-acting il-1 receptor antagonists
CA2849673A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
EP2794648A1 (en) * 2011-12-21 2014-10-29 Novo Nordisk A/S N-terminally modified insulin derivatives
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
SG11201500682WA (en) 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
PL2986313T3 (pl) * 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
BR112016017402A2 (pt) 2014-02-21 2017-10-17 Medimmune Ltd fusões anti-pcsk9~glp-1 e métodos para uso
JP2017525656A (ja) * 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CA2979617C (en) * 2015-03-19 2024-01-02 Institut De Cardiologie De Montreal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
AU2017207862B2 (en) 2016-01-13 2020-12-17 Novo Nordisk A/S EGF(A) analogues with fatty acid substituents
WO2019016306A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S BIFUNCTIONAL COMPOUNDS
CN111164098A (zh) 2017-07-19 2020-05-15 诺沃挪第克公司 Egf(a)类似物、其制品、制剂和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296694A2 (en) * 2008-04-23 2011-03-23 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
RU2528735C2 (ru) * 2008-09-12 2014-09-20 Ринат Ньюросайенс Корпорейшн Антагонисты pcsk9
WO2012177741A1 (en) * 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHAN L. et al. PCSK9 Binds to Multiple Receptors and Can Be Functionally Inhibited by an EGF-A Peptide; Biochem.&Biophys.Comm., 2008, v.375, n.1, p.69-73. *
ZHANG Y. et al. Calcium-independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain; J.Mol.Bio., 2012, v.422, p.685-696. *

Also Published As

Publication number Publication date
AU2017207862A1 (en) 2018-07-05
JP6797926B2 (ja) 2020-12-09
RS63298B1 (sr) 2022-07-29
JP2021035989A (ja) 2021-03-04
JP2019505521A (ja) 2019-02-28
WO2017121850A1 (en) 2017-07-20
US10822385B2 (en) 2020-11-03
US20200407409A1 (en) 2020-12-31
KR102417487B1 (ko) 2022-07-06
CA3010756A1 (en) 2017-07-20
PE20181376A1 (es) 2018-09-05
AU2017207862B2 (en) 2020-12-17
PH12018501502A1 (en) 2019-03-25
CO2018007440A2 (es) 2018-09-28
SI3402811T1 (sl) 2022-06-30
US20190016768A1 (en) 2019-01-17
IL260043A (en) 2018-07-31
ES2916998T3 (es) 2022-07-06
HUE058647T2 (hu) 2022-09-28
PL3402811T3 (pl) 2022-07-11
CN108473550B (zh) 2022-11-22
CL2018001868A1 (es) 2018-08-31
LT3402811T (lt) 2022-06-10
MX2018008681A (es) 2018-09-17
KR20180100177A (ko) 2018-09-07
BR112018013820A2 (pt) 2018-12-11
HRP20220720T1 (hr) 2022-09-30
RU2018127882A3 (enExample) 2020-06-19
DK3402811T3 (da) 2022-06-13
MY195199A (en) 2023-01-11
SA518391996B1 (ar) 2021-07-14
EP3402811A1 (en) 2018-11-21
EP3402811B1 (en) 2022-03-30
CN108473550A (zh) 2018-08-31
RU2018127882A (ru) 2020-02-13

Similar Documents

Publication Publication Date Title
RU2747877C2 (ru) Аналоги эфр(а) с заместителями - жирными кислотами
KR102379958B1 (ko) Gip 유도체 및 이의 용도
CN104311657B (zh) 双酰化glp-1衍生物
JP6352806B2 (ja) 新規のグルカゴン類似体
US11649269B2 (en) Bifunctional compounds comprising insulin peptides and EGF(A) peptides
EA020326B1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
CN101005857A (zh) 多肽延长标记
AU2012234276A1 (en) Novel glucagon analogues
KR20230104118A (ko) Glp-1 전구약물 및 이의 용도
US20200165313A1 (en) Egf(a) analogues, preparation, formulations and uses thereof
JP2020528049A (ja) 二機能性化合物
HK1262866B (en) Egf(a) analogues with fatty acid substituents